Signal Mining for Non-Bleeding Adverse Event in Novel Oral Anticoagulants: A Pharmacovigilance Study Based on the FAERS Database
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Backgroud : This study is based on the FAERS database and analyzes adverse events associated with NOACs from a real-world perspective, particularly focusing on non-bleeding adverse events (AEs) signals. Method : This study obtained raw data from the FAERS database, ranging from the third quarter of 2014 to the first quarter of 2024. The Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) methods were employed to detect potential signals between NOACs and AEs. Result : The significant adverse reaction signals were identified across three critical organ systems: Congenital, familial, and genetic disorders; Pregnancy, puerperium, and perinatal conditions; along with Blood and lymphatic system disorders. Furthermore, the analysis revealed distinct safety profiles among the different NOACs, with each exhibiting particular AE. Specifically, dabigatran was associated with adverse reactions including Potassium imbalance, Acidosis (n=21, ROR 025 =2.28, IC 025 =4.60), and Mental status changes (n=46, ROR 025 =1.67, IC 025 =5.85). For apixaban, there is a need for caution due to potential adverse reactions including Thyroid disorders (n=109, ROR 025 =1.79, IC 025 =6.28), Benign prostatic hyperplasia (n=57, ROR 025 =2.62, IC 025 =5.67), and Sleep disturbances (n=69, ROR 025 =1.24, IC 025 =5.87). Concerning edoxaban, practitioners should be vigilant about potential adverse effects such as Lymphatic disorder (n=3, ROR 025 =11.02, IC 025 =0.74), Rash morbilliform (n=69, ROR 025 =1.24, IC 025 =5.87), and Delirium (n=13, ROR 025 =1.54, IC 025 =3.81). Additionally, rivaroxaban usage may lead to complications such as Alopecia (n=959, ROR 025 =1.71, IC 025 =7.61), Menstrual irregularities, and Adrenomegaly (n=4, ROR 025 =2.49, IC 025 =1.36). Conclusion : This study has found that the non-bleeding adverse events associated with NOACs are linked to multiple organ systems, which requires high vigilance in clinical practice.